Neuroone Medical Technologies (NMTC) Depreciation & Amortization (CF) (2019 - 2026)

Neuroone Medical Technologies has disclosed Depreciation & Amortization (CF) across 8 years of filings, most recently posting $60029.0 for Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 8.54% year-over-year to $60029.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $256470.0 (down 0.59% YoY) and the FY2025 annual result came in at $261679.0, up 6.03% from the prior year.
• Depreciation & Amortization (CF) declined to $60029.0 in Q1 2026, from $65523.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $66594.0 in Q2 2025 and bottomed at $28531.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $60900.0 (2024), against an average of $54514.5.
• Year-over-year, Depreciation & Amortization (CF) jumped 87.03% in 2023 and declined 8.54% in 2026.
• Neuroone Medical Technologies' Depreciation & Amortization (CF) stood at $35889.0 in 2022, then soared by 63.44% to $58657.0 in 2023, then gained by 11.03% to $65127.0 in 2024, then grew by 0.61% to $65523.0 in 2025, then fell by 8.38% to $60029.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $60029.0, $65523.0, and $64324.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.